Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Hum Mol Genet
2008 Dec 01;1723:3728-39. doi: 10.1093/hmg/ddn269.
Show Gene links
Show Anatomy links
Molecular pathogenesis of megalencephalic leukoencephalopathy with subcortical cysts: mutations in MLC1 cause folding defects.
Duarri A, Teijido O, López-Hernández T, Scheper GC, Barriere H, Boor I, Aguado F, Zorzano A, Palacín M, Martínez A, Lukacs GL, van der Knaap MS, Nunes V, Estévez R.
???displayArticle.abstract???
Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a rare type of leukodystrophy, most often caused by mutations in the MLC1 gene. MLC1 is an oligomeric plasma membrane (PM) protein of unknown function expressed mainly in glial cells and neurons. Most disease-causing missense mutations dramatically reduced the total and PM MLC1 expression levels in Xenopus oocytes and mammalian cells. The impaired expression of the mutants was verified in primary cultures of rat astrocytes, as well as human monocytes, cell types that endogenously express MLC1, demonstrating the relevance of the tissue culture models. Using a combination of biochemical, pharmacological and imaging methods, we also demonstrated that increased endoplasmatic reticulum-associated degradation and endo-lysosomal-associated degradation can contribute to the cell surface expression defect of the mutants. Based on these results, we suggest that MLC1 mutations reduce protein levels in vivo. Since the expression defect of the mutants could be rescued by exposing the mutant-protein expressing cells to low temperature and glycerol, a chemical chaperone, we propose that MLC belongs to the class of conformational diseases. Therefore, we suggest the use of pharmacological strategies that improve MLC1 expression to treat MLC patients.
Ambrosini,
Biochemical characterization of MLC1 protein in astrocytes and its association with the dystrophin-glycoprotein complex.
2008, Pubmed
Ambrosini,
Biochemical characterization of MLC1 protein in astrocytes and its association with the dystrophin-glycoprotein complex.
2008,
Pubmed Barriere,
Plasticity of polyubiquitin recognition as lysosomal targeting signals by the endosomal sorting machinery.
2007,
Pubmed Ben-Zeev,
Megalencephalic leukoencephalopathy with subcortical cysts; a founder effect in Israeli patients and a higher than expected carrier rate among Libyan Jews.
2002,
Pubmed Blattner,
Clinical and genetic heterogeneity in megalencephalic leukoencephalopathy with subcortical cysts (MLC).
2003,
Pubmed Bodoy,
Identification of LAT4, a novel amino acid transporter with system L activity.
2005,
Pubmed
,
Xenbase Bonuccelli,
Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice.
2007,
Pubmed Boor,
MLC1 is associated with the dystrophin-glycoprotein complex at astrocytic endfeet.
2007,
Pubmed Boor,
MLC1: a novel protein in distal astroglial processes.
2005,
Pubmed Brown,
Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein.
1996,
Pubmed Burrows,
Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency.
2000,
Pubmed Chillarón,
An intracellular trafficking defect in type I cystinuria rBAT mutants M467T and M467K.
1997,
Pubmed
,
Xenbase Cohen,
Therapeutic approaches to protein-misfolding diseases.
2003,
Pubmed Drumm,
Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes.
1991,
Pubmed
,
Xenbase Estévez,
Barttin is a Cl- channel beta-subunit crucial for renal Cl- reabsorption and inner ear K+ secretion.
2001,
Pubmed
,
Xenbase Farinha,
Biochemical methods to assess CFTR expression and membrane localization.
2004,
Pubmed Gorospe,
Alexander disease and megalencephalic leukoencephalopathy with subcortical cysts: leukodystrophies arising from astrocyte dysfunction.
2006,
Pubmed Goutières,
Leukoencephalopathy, megalencephaly, and mild clinical course. A recently individualized familial leukodystrophy. Report on five new cases.
1996,
Pubmed Halet,
Imaging phosphoinositide dynamics using GFP-tagged protein domains.
2005,
Pubmed Ilja Boor,
Megalencephalic leukoencephalopathy with subcortical cysts: an update and extended mutation analysis of MLC1.
2006,
Pubmed Kaganovich,
Is the WKL1 gene associated with schizophrenia?
2004,
Pubmed Laing,
Degradation of connexin43 gap junctions involves both the proteasome and the lysosome.
1997,
Pubmed Leegwater,
Mutations of MLC1 (KIAA0027), encoding a putative membrane protein, cause megalencephalic leukoencephalopathy with subcortical cysts.
2001,
Pubmed Leegwater,
Identification of novel mutations in MLC1 responsible for megalencephalic leukoencephalopathy with subcortical cysts.
2002,
Pubmed Majem,
Control of E1A under an E2F-1 promoter insulated with the myotonic dystrophy locus insulator reduces the toxicity of oncolytic adenovirus Ad-Delta24RGD.
2006,
Pubmed McCarthy,
Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue.
1980,
Pubmed Meyer,
A missense mutation in a novel gene encoding a putative cation channel is associated with catatonic schizophrenia in a large pedigree.
2001,
Pubmed Montagna,
Vacuolating megalencephalic leukoencephalopathy with subcortical cysts: functional studies of novel variants in MLC1.
2006,
Pubmed
,
Xenbase Morello,
Pharmacological chaperones: a new twist on receptor folding.
2000,
Pubmed Nomura,
Prediction of the coding sequences of unidentified human genes. I. The coding sequences of 40 new genes (KIAA0001-KIAA0040) deduced by analysis of randomly sampled cDNA clones from human immature myeloid cell line KG-1.
1994,
Pubmed Pascual-Castroviejo,
Vacuolating megalencephalic leukoencephalopathy: 24 year follow-up of two siblings.
2005,
Pubmed Patrono,
Genetic heterogeneity of megalencephalic leukoencephalopathy and subcortical cysts.
2003,
Pubmed Riel-Romero,
Megalencephalic leukoencephalopathy with subcortical cysts in two siblings owing to two novel mutations: case reports and review of the literature.
2005,
Pubmed Saijo,
A case of megalencephalic leukoencephalopathy with subcortical cysts (van der Knaap disease): molecular genetic study.
2003,
Pubmed Schiffmann,
An update on the leukodsytrophies.
2001,
Pubmed Schiffmann,
The latest on leukodystrophies.
2004,
Pubmed Schmitt,
The brain-specific protein MLC1 implicated in megalencephalic leukoencephalopathy with subcortical cysts is expressed in glial cells in the murine brain.
2003,
Pubmed Sergent-Tanguy,
Fluorescent activated cell sorting (FACS): a rapid and reliable method to estimate the number of neurons in a mixed population.
2003,
Pubmed Sharma,
Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes.
2004,
Pubmed Singhal,
Megalencephalic leukoencephalopathy with subcortical cysts.
2003,
Pubmed Singhal,
Megalencephalic leukodystrophy in an Asian Indian ethnic group.
1996,
Pubmed Teijido,
Expression patterns of MLC1 protein in the central and peripheral nervous systems.
2007,
Pubmed Teijido,
Localization and functional analyses of the MLC1 protein involved in megalencephalic leukoencephalopathy with subcortical cysts.
2004,
Pubmed
,
Xenbase Topcu,
Megalencephaly and leukodystrophy with mild clinical course: a report on 12 new cases.
1998,
Pubmed Topçu,
Vacuoliting megalencephalic leukoencephalopathy with subcortical cysts, mapped to chromosome 22qtel.
2000,
Pubmed van der Knaap,
Leukoencephalopathy with swelling in children and adolescents: MRI patterns and differential diagnosis.
1995,
Pubmed van der Knaap,
Histopathology of an infantile-onset spongiform leukoencephalopathy with a discrepantly mild clinical course.
1996,
Pubmed van der Knaap,
Leukoencephalopathy with swelling and a discrepantly mild clinical course in eight children.
1995,
Pubmed
